文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

温度轨迹脓毒症亚表型的国际验证:纵向免疫与凝血模式及其对免疫球蛋白治疗的启示

International Validation of Temperature-Trajectory Sepsis Subphenotypes With Longitudinal Immune and Coagulation Patterns and Its Implications for Immunoglobulin Therapy.
PubMed 文献 · Crit Care Med · 2026-06-10
一句话结论在中国ICU队列中验证了美国开发的脓毒症温度轨迹四亚型,低温亚型死亡率最高(25%)且免疫球蛋白治疗显示一致获益方向(HR 0.47,p=0.03)。

本研究在中国一家三级医院ICU的2478例成人疑似感染患者中,回顾性验证了美国中心开发的脓毒症温度轨迹模型,将患者分为高热缓慢消退型(23%)、高热快速消退型(16%)、常温型(31%)和低温型(30%)。低温亚型死亡率最高(25%),并表现出最低的炎症反应、持续免疫抑制和凝血异常。倾向评分匹配后,免疫球蛋白治疗在不同亚型间效果异质,低温亚型显示一致获益方向(HR 0.47,p=0.03)。作者认为温度轨迹亚表型在国际队列中得到验证,不同亚型对免疫球蛋白治疗反应不同。

要点

  • 2478例成人ICU疑似感染患者分为四亚型:高热缓慢消退型567例(23%)、高热快速消退型397例(16%)、常温型780例(31%)、低温型734例(30%)。
  • 低温亚型死亡率最高(25%),并表现为持续低淋巴细胞计数和低单核细胞HLA-DR、持续凝血酶原时间和活化部分凝血活酶时间延长、最低血小板计数、纤维蛋白原和血红蛋白。
  • 免疫球蛋白治疗在不同亚型间效果异质,低温亚型显示一致获益方向(主要亚型分析:HR 0.47,p=0.03)。
  • 该温度轨迹模型在美国中心开发后在中国队列中得到国际验证。

适用人群与场景

  • 中国一家三级医院ICU的成人疑似感染患者,回顾性数据。

诊断标准与关键阈值

  • 基于温度轨迹的脓毒症亚表型分类:高热缓慢消退型、高热快速消退型、常温型、低温型。

研究设计与关键结果

  • 研究类型:回顾性验证研究;样本量2478例;单中心(中国一家三级医院ICU);人群为成人ICU疑似感染患者;无干预(观察性),并分析免疫球蛋白治疗的异质性效应。
  • 主要结果:低温亚型死亡率最高(25%),与既往发现一致。
  • 纵向免疫与凝血特征:低温亚型炎症反应最低(C反应蛋白低且快速下降、白细胞介素-6快速下降)、免疫抑制(淋巴细胞计数和单核细胞人类白细胞抗原-DR持续低)、凝血异常(凝血酶原时间和活化部分凝血活酶时间持续延长;血小板计数、纤维蛋白原和血红蛋白最低;红细胞输注率和剂量最高)。
  • 免疫球蛋白治疗异质性:低温亚型显示一致获益方向(主要亚型分析:HR 0.47,p=0.03)。

证据类型、等级与局限

  • 证据类型:回顾性验证研究(单中心,中国)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为温度轨迹亚表型在国际队列中得到验证,低温亚型死亡率最高且表现持续免疫功能障碍和凝血异常。
  • 作者认为不同亚表型对免疫球蛋白治疗反应不同。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Sepsis remains a major challenge in the ICU. Given the limitations of the one-size-fits-all strategy, precision medicine approaches are needed to identify distinct sepsis subtypes that may respond to different treatments. This study aimed to validate a temperature-trajectory model of sepsis developed in U.S. centers in a non-U.S. cohort from China, to characterize longitudinal immune and coagulation profiles, and to explore their potential value in guiding immunotherapy.

DESIGN: This study validated a previously developed sepsis temperature-trajectory model, delineated longitudinal immune and coagulation dynamics across distinct subphenotypes, and, after propensity score matching, examined the heterogeneous effects of immunoglobulin treatment.

SETTING: Retrospective data from a tertiary-care hospital ICU in China.

PATIENTS: Adult ICU patients with suspected infection.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Clinical and microbiological characteristics were compared across subphenotypes, and the interaction between subphenotype and immunoglobulin therapy on 30-day mortality was assessed. In total, 2478 patients were included and classified into four subphenotypes: hyperthermic slow resolvers (567; 23%), hyperthermic fast resolvers (397; 16%), normothermic (780; 31%), and hypothermic (HT, 734; 30%). The HT subphenotype exhibited the highest mortality rate (25%), consistent with previous findings. In longitudinal immune and coagulation profiling, the HT subphenotype exhibited the lowest inflammatory response (low and rapidly declining C-reactive protein and rapidly declining interleukin-6), suppressed immunity (persistently low lymphocyte counts and monocyte human leukocyte antigen-DR), and coagulation abnormalities (persistently prolonged prothrombin time and activated partial thromboplastin time; the lowest platelet counts, fibrinogen, and hemoglobin; and the highest rate and dose of RBC transfusion). Immunoglobulin therapy showed heterogeneous effects across different subphenotypes, with patients in the HT subphenotype showing a consistent direction of benefit (primary subtyping: hazard ratio, 0.47; p = 0.03).

CONCLUSIONS: The temperature-trajectory subphenotypes were validated in an international cohort. Patients in the HT subphenotype exhibited the highest mortality and showed persistent immune dysfunction and coagulopathy. Furthermore, different subphenotypes demonstrated distinct responses to immunoglobulin therapy.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Wang L, Pei F, Gu B, et al. International Validation of Temperature-Trajectory Sepsis Subphenotypes With Longitudinal Immune and Coagulation Patterns and Its Implications for Immunoglobulin Therapy. Crit Care Med. 2026. PMID: 42267870. doi:10.1097/CCM.0000000000007227

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。